Predictive polygenic score for outcome after first-line oxaliplatin-based chemotherapy in colorectal cancer patients using supervised principal component analysis.
Park HA, Edelmann D, Canzian F et al.
Publication Details
Comprehensive information about this research publication
Abstract
Summary of the research findings
Associations between candidate germline genetic variants and treatment outcome of oxaliplatin, a drug commonly used for patients with colorectal cancer, have been reported but not robustly established. This study aimed to construct polygenic hazard scores (PHSs) as predictive markers for oxaliplatin treatment outcome by using a supervised principal component approach (PCA).
2,547 European ancestry cases with oxaliplatin treatment, 118 European ancestry cases with other treatment, 134 Asian ancestry cases with oxaliplatin treatment, 6 Asian ancestry cases with other treatment, 213 African American cases with oxaliplatin treatment, 7 African American cases with other treatment, 73 cases with oxaliplatin treatment
Study Statistics
Key metrics and study information
Analysis
Comprehensive review of health and genetic findings
Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.
Analysis In Progress
Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.